Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 505

1.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G.

Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30785-5. doi: 10.1016/S1470-2045(19)30785-5. [Epub ahead of print]

PMID:
32027846
2.

Stability of lingual plate osteotomy in orthognathic surgery for patients with severe facial asymmetry: A retrospective analysis with 1-year follow-up.

Jeon HJ, Lee JS, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

J Craniomaxillofac Surg. 2020 Feb;48(2):156-161. doi: 10.1016/j.jcms.2019.12.014. Epub 2020 Jan 7.

PMID:
31980277
3.

On-beam computed tomography reconstruction for radiotherapy verification from projection image differences caused by motion during treatment.

Lee H, Cheong KH, Jung JW, Cho BC, Cho S, Yeo IJ.

Phys Med Biol. 2020 Jan 22. doi: 10.1088/1361-6560/ab6eb9. [Epub ahead of print]

PMID:
31968326
4.

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.

Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC.

Clin Lung Cancer. 2019 Dec 28. pii: S1525-7304(19)30374-2. doi: 10.1016/j.cllc.2019.12.006. [Epub ahead of print]

PMID:
31948903
5.

High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma.

Hong MH, Shin SJ, Shin SK, Kim DJ, Zo JI, Shim YM, Lee SE, Cho BC, Park SY, Choi YL, Kim HR.

Sci Rep. 2019 Dec 27;9(1):20197. doi: 10.1038/s41598-019-56828-7.

6.

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.

Kim SY, Lee JY, Kim DH, Joo H-, Yun MR, Jung D, Yun J, Heo SG, Ahn B-, Park CW, Pyo KH, Chun YJ, Hong MH, Kim HR, Cho BC.

Sci Rep. 2019 Dec 27;9(1):19909. doi: 10.1038/s41598-019-56356-4.

7.

Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.

de Perrot M, Wu L, Cabanero M, Perentes JY, McKee TD, Donahoe L, Bradbury P, Kohno M, Chan ML, Murakami J, Keshavjee S, Tsao MS, Cho BCJ.

J Thorac Cardiovasc Surg. 2019 Nov 13. pii: S0022-5223(19)32514-0. doi: 10.1016/j.jtcvs.2019.10.122. [Epub ahead of print]

PMID:
31866087
8.

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.

Leighl NB, Karaseva N, Nakagawa K, Cho BC, Gray JE, Hovey T, Walding A, Rydén A, Novello S.

Eur J Cancer. 2020 Jan;125:49-57. doi: 10.1016/j.ejca.2019.11.006. Epub 2019 Dec 12.

9.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators.

Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31838015
10.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators.

Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31838007
11.

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.

Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; RAPID Trial Investigators.

Lancet. 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5.

PMID:
31813635
12.

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.

J Clin Oncol. 2019 Dec 6:JCO1900457. doi: 10.1200/JCO.19.00457. [Epub ahead of print]

PMID:
31809241
13.

Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.

Kim HR, Park HJ, Son J, Lee JG, Chung KY, Cho NH, Shim HS, Park S, Kim G, In Yoon H, Kim HG, Jung YW, Cho BC, Park SY, Rha SY, Ha SJ.

J Immunother Cancer. 2019 Dec 4;7(1):339. doi: 10.1186/s40425-019-0785-8.

14.

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.

Chun YJ, Choi JW, Hong MH, Jung D, Son H, Cho EK, Min YJ, Kim SW, Park K, Lee SS, Kim S, Kim HR, Cho BC; Korean Lung Cancer Consortium (KLCC).

PLoS One. 2019 Nov 25;14(11):e0224379. doi: 10.1371/journal.pone.0224379. eCollection 2019.

15.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators.

N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.

PMID:
31751012
16.

The Effects of Helmet Therapy Relative to the Size of the Anterior Fontanelle in Nonsynostotic Plagiocephaly: A Retrospective Study.

Kim DG, Lee JS, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

J Clin Med. 2019 Nov 14;8(11). pii: E1977. doi: 10.3390/jcm8111977.

17.

Long-Term Outcomes of the Minimal Skin Incision Technique for Correcting Severe Microform and Minor-Form Cleft Lip With Philtrum Reconstruction Through the Intraoral Incision.

Cho BC, Kim YH, Tian L, Lee JS, Lee JW, Choi KY, Yang JD, Chung HY.

J Craniofac Surg. 2020 Jan/Feb;31(1):79-84. doi: 10.1097/SCS.0000000000005963.

PMID:
31725500
18.

Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node Metastasis.

Cho YA, Kim EK, Cho BC, Koh YW, Yoon SO.

Anticancer Res. 2019 Nov;39(11):6307-6316. doi: 10.21873/anticanres.13841.

PMID:
31704861
19.

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.

Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC.

EMBO Mol Med. 2019 Dec;11(12):e10581. doi: 10.15252/emmm.201910581. Epub 2019 Oct 21.

20.

The impact of patient blood management on blood utilization and clinical outcomes in complex spine surgery.

Visagie M, Qin CX, Cho BC, Merkel KR, Kajstura TJ, Amin RM, Purvis TE, Kebaish KM, Frank SM.

Transfusion. 2019 Dec;59(12):3639-3645. doi: 10.1111/trf.15544. Epub 2019 Oct 18.

PMID:
31625178
21.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ.

J Thorac Oncol. 2019 Oct 14. pii: S1556-0864(19)33529-4. doi: 10.1016/j.jtho.2019.10.002. [Epub ahead of print]

22.

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ.

Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7.

PMID:
31601496
23.

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC.

Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31587882
24.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y.

Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613.

PMID:
31582355
25.

Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis.

Cho BC, Kim DW, Park K, Lee JS, Yoo SS, Kang JH, Lee SY, Kim CH, Jang SH, Kim YC, Yoon HK, Han JY, Kim SW.

Curr Med Res Opin. 2020 Jan 19:1-6. doi: 10.1080/03007995.2019.1676708. [Epub ahead of print]

PMID:
31581843
26.

Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.

Kim YJ, Baek DS, Lee S, Park D, Kang HN, Cho BC, Kim YS.

Cancer Lett. 2019 Dec 1;466:23-34. doi: 10.1016/j.canlet.2019.09.005. Epub 2019 Sep 12.

PMID:
31521695
27.

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer.

Cho Y, Park S, Byun HK, Lee CG, Cho J, Hong MH, Kim HR, Cho BC, Kim S, Park J, Yoon HI.

Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1065-1073. doi: 10.1016/j.ijrobp.2019.08.047. Epub 2019 Aug 30.

PMID:
31476418
28.

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.

Kim DW, Lee DH, Han JY, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim JS, Min YJ, Cho JY, An HJ, Kim HG, Lee KH, Kim BS, Jang IJ, Yoon S, Han O, Noh YS, Hong KY, Park K.

Lung Cancer. 2019 Sep;135:66-72. doi: 10.1016/j.lungcan.2019.07.007. Epub 2019 Jul 9.

PMID:
31447004
29.

In Response.

Grant MC, Lester L, Cho BC.

Anesth Analg. 2019 Sep;129(3):e111. doi: 10.1213/ANE.0000000000004297. No abstract available.

PMID:
31425251
30.

Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.

Choe EA, Cha YJ, Kim JH, Pyo KH, Hong MH, Park SY, Shim HS, Jung I, Lee CY, Cho BC, Kim HR.

Lung Cancer. 2019 Oct;136:30-36. doi: 10.1016/j.lungcan.2019.07.027. Epub 2019 Aug 1.

PMID:
31421259
31.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.

PMID:
31405822
32.

NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma.

Kim EK, Cho YA, Seo MK, Ryu H, Cho BC, Koh YW, Yoon SO.

Sci Rep. 2019 Aug 2;9(1):11231. doi: 10.1038/s41598-019-47755-8.

33.

Effect of Keratinocytes on Myofibroblasts in Hypertrophic Scars.

Lee JS, Kim JS, Lee JW, Choi KY, Yang JD, Cho BC, Oh EJ, Kim TJ, Ko UH, Shin JH, Jeon S, Lee YJ, Chung HY.

Aesthetic Plast Surg. 2019 Oct;43(5):1371-1380. doi: 10.1007/s00266-019-01434-1. Epub 2019 Jul 25.

PMID:
31346713
34.

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.

Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS.

Cancer Res Treat. 2020 Jan;52(1):284-291. doi: 10.4143/crt.2019.200. Epub 2019 Jul 23.

35.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24.

PMID:
31339357
36.

A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.

Park JS, Hong MH, Chun YJ, Kim HR, Cho BC.

Lung Cancer. 2019 Aug;134:46-51. doi: 10.1016/j.lungcan.2019.05.030. Epub 2019 May 28.

PMID:
31319994
37.

Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors.

Kim G, Yoo M, Hong MH, Lee BW, Kang ES, Cha BS, Kim HR, Lee YH, Cho BC.

Cancer Chemother Pharmacol. 2019 Aug;84(2):405-414. doi: 10.1007/s00280-019-03889-0. Epub 2019 Jun 27.

PMID:
31250153
38.

How do I audit intraoperative blood component utilization in cardiac surgery?

Hensley NB, Cho BC, Visagie M, Lester LC, Abernathy JH 3rd, Frank SM.

Transfusion. 2019 Oct;59(10):3058-3064. doi: 10.1111/trf.15399. Epub 2019 Jun 14.

PMID:
31198989
39.

A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer.

Munoz-Schuffenegger P, Kandel S, Alibhai Z, Hope A, Bezjak A, Sun A, Simeonov A, Cho BCJ, Giuliani M.

Clin Oncol (R Coll Radiol). 2019 Oct;31(10):720-727. doi: 10.1016/j.clon.2019.05.014. Epub 2019 Jun 5.

PMID:
31176537
41.

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Gomez DR, Rimner A, Simone CB 2nd, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig K.

J Thorac Oncol. 2019 Jul;14(7):1172-1183. doi: 10.1016/j.jtho.2019.03.030. Epub 2019 May 22. Review.

PMID:
31125736
42.

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer.

Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC.

Yonsei Med J. 2019 Jun;60(6):525-534. doi: 10.3349/ymj.2019.60.6.525.

43.

On-label compared to off-label four-factor prothrombin complex concentrate use: a retrospective, observational study.

Cho BC, Jung YH, DeMario VM, Lau E, Podlasek SJ, Grant MC, Gehrie EA, Frank SM.

Transfusion. 2019 Aug;59(8):2678-2684. doi: 10.1111/trf.15355. Epub 2019 May 23.

PMID:
31121073
44.

Usefulness of the LigaSure™ small jaw sealing device for breast reconstruction with a latissimus dorsi flap.

Lee JS, Kim DG, Lee JW, Choi KY, Chung HY, Cho BC, Yang JD.

J Plast Surg Hand Surg. 2019 Oct;53(5):295-300. doi: 10.1080/2000656X.2019.1612753. Epub 2019 May 7.

PMID:
31062994
45.

Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma.

Lim SM, Choi JW, Hong MH, Jung D, Lee CY, Park SY, Shim HS, Sheen S, Kwak KI, Kang DR, Cho BC, Kim HR.

Lung Cancer. 2019 May;131:139-146. doi: 10.1016/j.lungcan.2019.04.002. Epub 2019 Apr 3.

PMID:
31027691
46.

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.

Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, Lee CY, Park SY, Park SH, Cho BC, Shim HS, Shin EC, Kim HR.

Ann Oncol. 2019 Jul 1;30(7):1104-1113. doi: 10.1093/annonc/mdz123.

PMID:
30977778
47.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.

48.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators.

Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

PMID:
30955977
49.

Application of Cultured Epidermal Homograft (Kaloderm) for Wide Scar Treatment.

Lee JS, Chu SG, Lee JW, Choi KY, Yang JD, Cho BC, Jeon S, Chung HY.

J Craniofac Surg. 2019 Sep;30(6):e535-e539. doi: 10.1097/SCS.0000000000005485.

PMID:
30939560
50.

Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors.

Lee HW, Choi B, Kang HN, Kim H, Min A, Cha M, Ryu JY, Park S, Sohn J, Shin K, Yun MR, Han JY, Shon MJ, Jeong C, Chung J, Lee SH, Im SA, Cho BC, Yoon TY.

Nat Biomed Eng. 2018 Apr;2(4):239-253. doi: 10.1038/s41551-018-0212-3. Epub 2018 Apr 2.

PMID:
30936439

Supplemental Content

Loading ...
Support Center